TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03177993
Drug: 3 drug dose - IDA with second dose of ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA). Eight days after treatment participants will be given a second dose of ivermectin alone.~Participants excluded from ivermectin will receive a topical dose of permethrin cream both on day 0 and day 8.~Exclusion criteria for ivermectin, diethylcarbamazine and albendazole:~* severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~* allergy to ivermectin, diethylcarbamazine or albendazole;~* pregnant;~* breastfeeding within 7 days of delivery;~* less than 2 years old; OR~* less than 15 kg~In addition if less than 5 years old excluded from ivermectin.~Exclusion criteria for permethrin:~* allergy to permethrin~* crusted scabies
Study: NCT03177993
Drug: 2 drug dose - DA
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine, and albendazole (DA).~If scabies is present in the participant or a household member permethrin cream will be provided 8 days after dose of DA.~Exclusion criteria for diethylcarbamazine and albendazole:~* severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~* allergy to diethylcarbamazine or albendazole;~* pregnant;~* breastfeeding within 7 days of delivery;~* less than 2 years old; OR~* less than 15 kg~Exclusion criteria for permethrin:~* allergy to permethrin~* crusted scabies
Study: NCT00801827
Drug: F-18 (fallypride)
Normalized name: F-18 fallypride
DrugBank: Florbetaben F-18 (DB09148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects undergoing bariatric surgery will have Positron Emission Tomography (PET)scans of their brains using the radioligand fallypride before and after the operation.
Study: NCT04180982
Drug: SHR4640 dose1 plus Febuxostat dose1
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet,dose1,QD
Study: NCT04180982
Drug: SHR4640 dose1 plus Febuxostat dose2
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet,dose1, dose2 QD
Study: NCT04180982
Drug: SHR4640 dose2 plus Febuxostat dose3
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet,dose2, dose3 QD
Study: NCT03120624
Drug: Ruxolitinib Phosphate
Normalized name: Ruxolitinib Phosphate
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03120624
Drug: Technetium Tc-99m Sodium Pertechnetate
Normalized name: TECHNETIUM TC-99M SODIUM PERTECHNETATE
DrugBank: Technetium Tc-99m pertechnetate (DB09314)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00206674
Drug: Sargramostim (Leukine)
Normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6µg/kg SARGRAMOSTIM subcutaneous daily for 8 weeks
Study: NCT03136068
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trans-abdominal injection
Study: NCT00734305
Drug: MM-121
Normalized name: 2X-121
DrugBank: 2X-121 (DB16063)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation Frequency - once weekly
Study: NCT01071395
Drug: Amantadine
Normalized name: Amantadine
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadine hydrochloride 300mg daily in three divided doses
Study: NCT02805257
Drug: Mitomycin-C
Normalized name: Mitomycin-C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative and postoperative injections of mitomycin-c/Mitosol
Study: NCT01076400
Drug: adavosertib
Normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adavosertib capsules are administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle.
Study: NCT01076400
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topotecan is administered at a dosage of 0.75 mg/m\^2 by intravenous (IV) infusion over 30 minutes on Days 1-3.
Study: NCT01076400
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin is administered at a dosage of 50 mg/m\^2 by IV infusion over 30 minutes on Day 1.
Study: NCT01076400
Drug: Placebo to adavosertib
DrugBank: Adavosertib (DB11740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to adavosertib capsules are administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle.
Study: NCT02766608
Drug: BD MDI 320 μg
Normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blinded Treatment
Study: NCT02239510
Drug: Senna
Normalized name: Senna
DrugBank: Senna leaf (DB15889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule (50 mg) Senna daily for 12 weeks
Study: NCT02239510
Drug: Linzess
Normalized name: Linzess
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 capsule (145 mcg) of Linzess once daily for 12 weeks
Study: NCT03391843
Drug: FOLFOXIRI+Cetuximab regimen
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: FOLFOXIRI+Cetuximab Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h +Cetuximab 500mg/m²,all on day 1 of each 2 weeks cycle
Study: NCT02343458
Drug: GFF MDI (PT003)
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI; PT003); Glycopyrronium and Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
Study: NCT02343458
Drug: FF MDI (PT005)
Normalized name: FF-10101-01
DrugBank: FF-10101-01 (DB16050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
Study: NCT02607579
Drug: Exparel
Normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02607579
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02326103
Drug: Ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of ciprofloxacin with placebo in alcoholic hepatitis
Study: NCT00464542
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg, taken by mouth, two times a day, 7 days
Study: NCT01043874
Drug: Nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg BID
Study: NCT00475826
Drug: Statins and Ezetimibe
Normalized name: atorvastatin and ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02818738
Drug: Levamisole Hydrochloride
Normalized name: Levamisole Hydrochloride
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage : 5, 10, 25 et 50 mg. Dosage form : oral tablets, coated and non dividable for taste-masking Posology : 2.5 mg/kg on alternate days maximum 150mg. Treatment duration : 6 months
Study: NCT03936491
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate is a central nervous system stimulant used for the therapy of attention deficit disorder and narcolepsy.
Study: NCT03936491
Drug: Atomoxetine
Normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine is a medication used to treat attention deficit hyperactivity disorder (ADHD).\[6\] Use is only recommended in those who are at least six years old.\[6\] It is taken by mouth.\[6\]
Study: NCT01265953
Drug: SFN-rich broccoli sprout extract capsules
Normalized name: broccoli sprout extract
DrugBank: Broccoli (DB10511)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four weeks SFN-rich broccoli sprout extract (BSE) capsules: 200µmol of SFN, 2 capsules (1 capsule B.I.D.) daily
Study: NCT04134663
Drug: vasoconstrictor and oxytocin treatment
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intransal administration of vasoconstrictor and oxytocin
Study: NCT04134663
Drug: vasoconstrictor's placebo and oxytocin treatment
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intransal administration of vasoconstrictor's placebo and oxytocin
Study: NCT04134663
Drug: vasoconstrictor and oxytocin's placebo treatment
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intransal administration of vasoconstrictor and oxytocin's placebo
Study: NCT00182689
Drug: sorafenib tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT01610700
Drug: GW-1000-02
Normalized name: GW-559090
DrugBank: GW-559090 (DB06508)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. The maximum permitted dose of study medication was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
Study: NCT00123227
Drug: Rosiglitazone
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02861690
Drug: Liposomal Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients received Liposomal Paclitaxel 175mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.
Study: NCT02861690
Drug: Nedaplatin
Normalized name: Nedaplatin
DrugBank: Nedaplatin (DB13145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received Nedaplatin80mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.
Study: NCT01979926
Drug: Combination of Broussonetia spp and Lonicera spp
Normalized name: CAPSICUM SPP.
DrugBank: Capsicum (DB10897)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/ day or 1200 mg/ day for 7 days
Study: NCT02401256
Drug: Montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements.
Study: NCT02743637
Drug: SDX-7320
Normalized name: METAP2 inhibitor SDX-7320
DrugBank: Evexomostat (DB19140)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDX-7320 is a synthetic copolymer-drug conjugate of a novel MetAP2 inhibitor.
Study: NCT03472534
Drug: diacerein 1% ointment
DrugBank: Diacerein (DB11994)
Approvals — FDA: no, EMA: no, PMDA: no
Description: diacerein 1% ointment applied to the skin of the infrascapular area of the back under occlusive patch for 21 days.
Study: NCT01389908
Drug: olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive doses within the range of 280 mg to 405mg OP Depot, according the physician's judgment, on a 3-week interval.
Study: NCT00359112
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00359112
Drug: Avandamet
Normalized name: Avandamet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01319929
Drug: LY2828360
Normalized name: LY2828360
DrugBank: LY2828360 (DB16074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04120506
Drug: VPRIV
Normalized name: Vpriv
DrugBank: Velaglucerase alfa (DB06720)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Safety, pharmacokinetics, and efficacy of rapid intravenous infusion of velaglucerase alfa (VPRIV) in adult patients with type 1 Gaucher disease
Study: NCT02188017
Drug: Acthar gel
Normalized name: Acthar Gel
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given 80 units daily for 10 days, then randomized to receive either 40 or 80 units twice a week
Study: NCT00272701
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00272701
Drug: Other PPI marketed in Sweden
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00487110
Drug: Tropisetron
Normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a comparison of the analgesic action of paracetamol versus tropisetron+paracetamol
Study: NCT00487110
Drug: paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a comparison of the analgesic action of paracetamol versus tropisetron+paracetamol
Study: NCT03811912
Drug: CTP-543
Normalized name: CTP-SOMATROPIN FUSION PROTEIN
DrugBank: Somatrogon (DB14960)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: CTP-543 administered as 8 mg tablet.
Study: NCT01156753
Drug: CDX-011
Normalized name: CDX
DrugBank: Cefadroxil (DB01140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CDX-011 (1.88 mg/kg) administered as an intravenous infusion on Day 1 of each 21 day cycle.
Study: NCT01016795
Drug: r-metHuSCF and Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
Study: NCT01016795
Drug: Chemotherapy plus Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
Study: NCT01782131
Drug: Posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: POS IV: Day 1: 300 mg BID Day 2-84: 300 mg QD POS oral: Day 1: 300 mg BID Day 2-84: 300 mg QD
Study: NCT01782131
Drug: Voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VOR IV: Day 1: 6 mg/kg per body weight administered BID Day 2-84: 4 mg/kg per body weight administered BID VOR oral: Day 1: 300 mg BID Day 2-84: 200 mg BID
Study: NCT04367168
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine 1mg, 1 ½ pill in day 1 and ½ pill BID during 10 days in both mild and severe COVID-19
Study: NCT02627677
Drug: Ponatinib 30 mg QD
Normalized name: PONATinib 30 MG
DrugBank: Ponatinib (DB08901)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ponatinib 30 mg, taken orally once daily.
Study: NCT02627677
Drug: Ponatinib 15 mg QD
Normalized name: PONATinib 15 MG
DrugBank: Ponatinib (DB08901)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ponatinib 15 mg, taken orally once daily.
Study: NCT02627677
Drug: Nilotinib 400 mg BID
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib 400 mg, taken orally twice daily.
Study: NCT03102398
Drug: TR-399 (5% Vardenafil HCl·3H2O, topical gel)
Normalized name: Vardenafil Hydrochloride
DrugBank: Vardenafil (DB00862)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5% Vardenafil HCl·3H2O, topical gel, 2 drops (50ul, 2.5mg), q.d.
Study: NCT01390012
Drug: Dexamethasone tablet 6 mg
Normalized name: dexamethasone Oral Tablet
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone tablet 6 mg
Study: NCT01390012
Drug: Dexamethasone injection 4 mg
Normalized name: dexamethasone Injection
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone injection 4 mg
Study: NCT00384085
Drug: Insulin Glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous injection up to 1 injection per day
Study: NCT00384085
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous injection once-a-day
Study: NCT00384085
Drug: Premixed Insulin
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous injection twice-a-day.
Study: NCT00384085
Drug: Insulin Glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous injection up to 3 injections per day.
Study: NCT02451748
Drug: Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CDP870, tradename Cimzia) or is provided in prefilled syringes at the dose of 200mg.~Patients received 2x200mg at weeks 0, 2 and 4. Additionally a maintenance dose of 200mg is given every 2 weeks. Treatment is performed through subcutaneous injection.
Study: NCT02451748
Drug: Certolizumab pegol (CDP870, tradename Cimzia)
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: rtolizumab pegol (CDP870, tradename Cimzia) or is provided in prefilled syringes at the dose of 200mg.~Patients received 2x200mg at weeks 0, 2 and 4. Additionally a maintenance dose of 200mg is given every 2 weeks. Treatment is performed through subcutaneous injection.
Study: NCT02451748
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: some patients are on 400mg/day of hydroxychloroquine.
Study: NCT02451748
Drug: Sulfasalazine
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: some patients are on 300 mg/day and some patients are on 1000 mg/day dose of sulfasalazine
Study: NCT02451748
Drug: Medrol
Normalized name: Medrol
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: some patients are on 8mg/day of medrol
Study: NCT02451748
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: some patients are on 10mg /day, some patients are on 20 mg/day, some patients are on 2.5 mg/day, some patients are on 30 mg/day, and some patients are on 5 mg/day of prednisone
Study: NCT02451748
Drug: Triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: some patients are on Triamcinolone 40-80mg IM monthly (received 40mg dose 1 week before blood draw, off enbrel 50mg weekly and SSZ 1000mg bid for \~ 3 months) some patients are on Triamcinolone 40mg IM monthly
Study: NCT02451748
Drug: Leflunomide
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: some patients are on 20mg/day of leflunomide
Study: NCT02451748
Drug: humira
Normalized name: Humira
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: some patients are on Humira 40mg q2weeks
Study: NCT03696121
Drug: Desmopressin Injection
Normalized name: desmopressin Injection
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose 20 micrograms in 50ml Normal Saline as intravenous injection infused over 20 minutes
Study: NCT02875587
Drug: Cabergoline
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabergoline (Dostinex; Pfizer, Italy) at a daily dose of 0.5 mg is administered orally at bed time for 8 days starting on the day of HCG administration
Study: NCT02875587
Drug: Calcium gluconate
Normalized name: Calcium Gluconate
DrugBank: Calcium gluconate (DB11126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous 10% calcium gluconate, 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1, day 2, and day 3 after ovum pickup. Intravenous infusion will be performed within 30 minutes.
Study: NCT01073618
Drug: voriconazole IV
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 mg/kg iv q 12 hours (loading) then maintenance
Study: NCT01427244
Drug: trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: monoclonal antibody
Study: NCT02318329
Drug: FPA144
Normalized name: Anti-fgfr2 monoclonal antibody fpa144
DrugBank: Bemarituzumab (DB16105)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPA144 will be administered by IV infusion over approximately 30 minutes every 2 weeks.
Study: NCT03313804
Drug: Immune checkpoint inhibitor
Normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care immune checkpoint inhibitor
Study: NCT00014573
Drug: carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00014573
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00014573
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00859898
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets, Oral, 10 mg, once daily, 24 weeks
Study: NCT00859898
Drug: Metformin XR
Normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, up to 2000 mg, once daily, 24 weeks